Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
Navidea Biopharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: August 2, 2021
Navidea Biopharmaceuticals reported fiscal year 2020 executive compensation information on August 2, 2021.
In 2020, three executives at Navidea Biopharmaceuticals received on average a compensation package of $618K, a 46% increase compared to previous year.
Jed A. Latkin, Chief Executive Officer, received $1.2M in total, which increased by 66% compared to 2019. 39% of Latkin's compensation, or $482K, was in salary. Latkin also received $253K in non-equity incentive plan, $322K in option awards, $163K in stock awards, as well as $5.7K in other compensation.
Joel H. Kaufman, Chief Business Officer, received a compensation package of $326K, which increased by 19% compared to previous year. 69% of the compensation package, or $226K, was in salary.
Michael S. Rosol, Chief Medical Officer, earned $302K in 2020, a 21% increase compared to previous year.